ADMA Biologics: Almost ready to run between the toes of Giants

  Contents Introduction to the Investment Thesis. 2018 is the make-or-break year For ADMA. ADMA has transformed its strategic positioning through the BTBU transaction. Primary Immune Deficiency and the adaptive immune system. RI-002 is a “super immune-globulin” RI-002’s phase III results “batted the ball out of the park”  With Phase III results that “batted the…

Research thesis on ADMA Biologics (Ticker: ADMA US Equity)

ading the right users